Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2026 Earnings Call Transcript
Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2026 Q1 Earnings Call. [Operator Instructions] Please note, this conference is being recorded.
Aytu Biopharma Inc (AYTU)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 1,086,812 | $2,043,207 | 0.07% | |
| 2. | Stonepine Capital Timothy P. Lynch | 891,855 | $1,676,687 | +10% | 1.36% |
| 3. | Diadema Partners Timothy Beau Bassett | 272,670 | $512,620 | 0.13% | |
| 4. | Renaissance Technologies Jim Simons | 95,123 | $178,831 | +6% | 0% |
| 5. | Persistent Asset Partners Xin Huang | 62,452 | $117,410 | 0.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.92 | 10,000 | $9,230.00 | 50 | 2020-11-18 | Filing | |
| $1.50 | 16,666 | $24,999.00 | 29,462 | 2025-06-09 | Filing | |
| $1.50 | 66,666 | $99,999.00 | 153,257 | 2025-06-09 | Filing | |
| $1.30 | 15,000 | $19,500.00 | 86,591 | 2025-02-28 | Filing | |
| $1.87 | 12,000 | $22,428.00 | 21,935 | 2023-06-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.01 | 209 | $1,256.09 | 0 | 2020-12-30 | Filing | |
| $0.00 | 0 | $0.00 | 0 | 2020-04-27 | Filing | |
| $1.82 | 5,108,921 | $9,298,236.22 | 0 | 2020-04-27 | Filing | |
| $1.55 | 92,777 | $144,091.96 | 9,713,068 | 2020-04-15 | Filing | |
| $0.00 | 0 | $0.00 | 1 | 2020-03-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 619,574 | $1,164,799 | 0.11% | |
| 2. | 278,583 | $523,736 | 0% | |
| 3. | 71,006 | $133,516 | 0% | |
| 4. | 68,736 | $129,224 | 0% | |
| 5. | 30,964 | $58,213 | 0% |
News See All
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2025 Earnings Call Transcript
Operator: Greetings. Welcome to the Aytu BioPharma, Inc. report for fiscal 2025 full year and fourth quarter operational and financial results on September 23, 2025, conference call.
Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition
Aytu BioPharma, Inc. (NASDAQ:AYTU) is one of the best high-return penny stocks to buy now.
11 Best High Return Penny Stocks to Buy Now
US equity markets are back at all-time highs amid a muted response to new U.S. tariffs and the trade war. The Nasdaq Composite Index, performing relatively well among major U.S.
Aytu Boosts Liquidity with Eclipse Loan Extension
Aytu BioPharma, Inc. (NASDAQ:AYTU) is among the best growth stocks to invest in for the next 5 years. On Monday, Aytu BioPharma, Inc.
15 Best Growth Stocks to Invest in for the Next 5 Years
Before making any decision, whether big or small, we instinctively weigh its long-term impact, and this is particularly true in the case of stocks.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2025 Earnings Call Transcript
Operator: Greetings. And welcome to the Aytu BioPharma Fiscal 2025 Q3 Earnings Call. At this time, all participants are in a listen-only.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2025 Earnings Call Transcript
Operator: Good day, everyone, and welcome to the Aytu BioPharma Fiscal 2025 Q2 Earnings Call. At this time, all participants have been placed on a listen-only.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript
Operator: Greetings. Welcome to the Aytu BioPharma Fiscal 2025 Q1 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q4 2024 Earnings Call Transcript
Operator: Greetings, welcome to the Aytu BioPharma's Fiscal 2024 Q4 Earnings Call. At this time, all participants have been placed on a listen-only mode.
Hedge Fund Resource Center Billionaire Hedge Funds
